Wuhan YZY Biopharma Co., Ltd. (02496) published its Monthly Return on Movements in Securities for the period ended 31 October 2025. The total authorized share capital remained at RMB 193,849,200, comprising 111,468,814 H shares, 75,510,642 domestic shares, and 6,869,744 unlisted foreign shares, all with par value of RMB 1. No changes occurred in the issued share capital during the reporting month.

Additionally, the 2024 H Share Option Plan, adopted on 27 June 2024, had 3,050,000 outstanding share options at month-end. No new shares were issued or transferred from treasury under the plan during October 2025. The plan retains the potential to issue up to 16,334,800 new shares upon exercise of all currently authorized share options.